前列腺MRI引导立体定向放疗的纯MRI模拟工作流
本研究开发并验证了一种端到端纯MRI工作流,以前列腺癌患者为对象,用3 T MRI模拟生成合成CT(sCT),替代计划CT,并在0.35 T MR-Linac上实施治疗。结果显示该工作流临床可行,sCT与pCT剂量学高度一致,可减少患者负担并提升流程效率。
要点
- 纯MRI模拟用3 T MRI生成sCT,替代计划CT,简化前列腺SMART流程。
- 10例患者验证显示sCT与pCT剂量学高度一致,γ通过率优良。
- 该工作流保留3 T高分辨勾画与MR引导,临床可行且剂量学稳健。
核心结论
- 整合3 T MR模拟与0.35 T MR-Linac治疗的sCT路径临床可行且剂量学稳健。
- 纯MRI模拟减少患者负担并提升工作流效率。
- 该路径维持了SMART方案所依赖的高质量3 T勾画与MR引导。
研究设计与样本
- 开发并验证端到端纯MRI工作流,纳入10例前列腺癌患者。
- 患者在3 T Siemens MAGNETOM Vida MRI上模拟,获取T2加权BLADE/DWI及T1加权DIXON VIBE序列。
- 用FDA批准的深度学习算法由T1加权DIXON VIBE生成sCT。
- 单次3 T模拟数据集用于计划并在ViewRay MRIdian 0.35 T MR-Linac上实施治疗。
- 回顾性将基于pCT的计划在sCT上重算,用剂量体积直方图和三维γ指数分析评估剂量一致性。
主要发现
- 完整工作流临床实施成功。
- sCT与pCT计算之间剂量学验证显示高保真度。
- γ指数为96.80%±1.33%(2%剂量偏差、2 mm剂量一致性、10%阈值、局部剂量归一化)。
- γ指数为99.98%±0.03%(3%剂量偏差、2 mm剂量一致性、10%、全局)。
- 计划靶区D95%平均绝对差异小(0.06±0.14 Gy)。
临床怎么用
- 前列腺癌SMART可采用纯MRI模拟替代计划CT,以简化流程并减少患者负担。
- 用3 T MRI生成sCT后可在0.35 T MR-Linac上计划与治疗,保留高场勾画优势。
- 实施前应验证sCT剂量学一致性,可参考γ指数与靶区D95%差异指标。
局限性
- 验证仅纳入10例前列腺癌患者,样本量有限。
- pCT计划在sCT上为回顾性重算,非前瞻性随机比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) protocol for prostate stereotactic body radiation therapy has demonstrated favorable clinical outcomes using a 3 T MR imaging (MRI) for delineation and a 0.35 T MR-Linac for adaptation, addressing challenges associated with low-field MRI delineation. However, this workflow necessitates 3 distinct simulation scans (computed tomography [CT], 3 T MRI, and 0.35 T MRI), resulting in logistical complexity and inefficiency. To address these limitations, we have developed and validated an end-to-end MR-only workflow to eliminate the need for a planning CT scan (pCT), thereby streamlining treatment delivery and reducing patient burden. METHODS AND MATERIALS: A workflow was developed, wherein 10 prostate cancer patients were simulated on a 3 T Siemens MAGNETOM Vida MRI scanner. Consistent with the SMART protocol, high-resolution T2-weighted BLADE/DWI sequences were used for definitive urethra/dominant intraprostatic lesion delineation, and additionally, a T1-weighted DIXON VIBE sequence was acquired to generate a synthetic CT (sCT) using an FDA-approved deep-learning-based algorithm. This single 3 T simulation data set was used to plan and subsequently deliver treatment on the ViewRay Systems MRIdian 0.35 T MR-Linac. To validate this CT-free pathway, pCT-based plans were retrospectively recalculated on the sCTs. Dosimetric agreement was assessed using dose-volume histogram analysis and 3-dimensional gamma index analysis. RESULTS: Clinical implementation of the full workflow was successful. Dosimetric validation demonstrated high fidelity between sCT and pCT calculations. Computed γ-indices were 96.80%±1.33% (2% dose deviation, 2 mm dose-to-agreement, 10% threshold, local dose normalization) and 99.98%±0.03% (3%dosedeviation,2mm dose-to-agreement, 10%, global). Mean absolute differences in planning target volume D95% were small (0.06±0.14 Gy). CONCLUSIONS: Integrating high-field 3 T MR simulation with 0.35 T MR-Linac delivery via an sCT pathway is clinically feasible and dosimetrically robust. MRI-only simulation reduces patient burden and improves workflow efficiency, while maintaining the high-quality 3 T delineation and MR guidance that defines the SMART approach.
引用
- Kinz M, Campbell J, Bullens CL, et al. Magnetic Resonance Imaging-Only Simulation for Prostate Magnetic Resonance Imaging-Guided Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2026. PMID: 42419395. doi:10.1016/j.prro.2026.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。